You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

idelalisib

Showing 1 - 25 of 68
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Lymphocytic Leucemia Trial in Cologne (Bendamustine, GA101, CAL-101)

Active, not recruiting
  • Chronic Lymphocytic Leucemia
  • Cologne, Germany
    German CLL Study Group
Apr 29, 2022

Recurrent Chronic Lymphoid Leukemia Trial in Boston (ACY-1215, Ibrutinib, Idelalisib)

Active, not recruiting
  • Recurrent Chronic Lymphoid Leukemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 19, 2022

Diffuse Large B Cell Lymphoma Trial in Denmark, Sweden (Idelalisib)

Completed
  • Diffuse Large B Cell Lymphoma
  • Idelalisib
  • Aarhus C, Denmark
  • +5 more
Oct 12, 2021

Chronic Lymphocytic Leukemia, CLL, Relapsed CLL Trial (Dose combination 1-1, dose combination 1-2, Dose combination 1-3)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Dose combination 1-1
  • +5 more
  • (no location specified)
Nov 1, 2021

Metastatic Colorectal Cancer Trial in Oslo (Alectinib, Cetuximab, Crizotinib)

Recruiting
  • Metastatic Colorectal Cancer
  • Oslo, Norway
    Oslo University Hospital
Feb 10, 2023

Chronic Lymphocytic Leukemia Trial in Germany (Tirabrutinib, Idelalisib, Obinutuzumab)

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • Frankfurt, Brandenburg, Germany
  • +13 more
Dec 24, 2021

Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Worldwide (Loncastuximab Tesirine, Idelalisib)

Active, not recruiting
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Loncastuximab Tesirine
  • Idelalisib
  • Las Vegas, Nevada
  • +33 more
Jul 26, 2022

Acute Lymphoblastic Leukemia Trial in Spain (Idelalisib)

Terminated
  • Acute Lymphoblastic Leukemia
  • Idelalisib
  • Badalona, Spain
  • +11 more
Sep 2, 2021

Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide

Completed
Has Results
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +2 more
  • Tafasitamab
  • +2 more
  • Jacksonville, Florida
  • +16 more
Dec 10, 2021

Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma Trial in United

Terminated
Has Results
  • Previously Untreated Pancreatic Ductal Adenocarcinoma
  • Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
  • Idelalisib
  • +2 more
  • Scottsdale, Arizona
  • +8 more
Mar 31, 2021

Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma Trial in Aichi, Miyagi, Tokyo (Idelalisib)

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Idelalisib
  • Aichi, Japan
  • +2 more
Feb 24, 2021

Chronic Lymphocytic Leukemia Treated With Idelalisib and

Completed
  • Chronic Lymphocytic Leukemia
  • idelalisib and rituximab
  • Cona, Ferrara, Italy
  • +37 more
May 11, 2022

Chronic Lymphocytic Leukemia (CLL) Trial in Columbus, Salt Lake City (Idelalisib, BI 836826)

Terminated
Has Results
  • Chronic Lymphocytic Leukemia (CLL)
  • Idelalisib
  • BI 836826
  • Columbus, Ohio
  • +1 more
Nov 23, 2020

Occurrence and Concentrations of Ibrutinib and Idelalisib

Completed
  • Hematological Malignancies
  • Blood samples for pharmacokinetics exploration
  • +7 more
  • Toulouse, France
    Cancer University Institute of Toulouse Oncopole
Dec 24, 2020

Follicular Lymphoma Trial in Worldwide (Idelalisib)

Active, not recruiting
  • Follicular Lymphoma
  • Idelalisib
  • Woodville South, South Australia, Australia
  • +65 more
Aug 24, 2022

Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma Trial in Miami, Baltimore, Milwaukee (Zydelig)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +8 more
  • Miami, Florida
  • +2 more
Apr 21, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • Scottsdale, Arizona
  • +1 more
Aug 10, 2021

Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma Trial in United States (20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016

Terminated
  • Chronic Lymphocytic Leukemia
  • Peripheral T-cell Lymphoma
  • 20 mg/kg TRU-016 + Rituximab
  • +5 more
  • Augusta, Georgia
  • +7 more
May 18, 2021

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in United States (Idelalisib,

Completed
Has Results
  • Indolent Non-Hodgkin's Lymphoma
  • +2 more
  • Idelalisib
  • +8 more
  • Huntsville, Alabama
  • +10 more
Feb 22, 2021

Myelofibrosis Trial in Stanford, Ann Arbor (Idelalisib, Ruxolitinib)

Terminated
Has Results
  • Myelofibrosis
  • Stanford, California
  • +1 more
Aug 31, 2020

Chronic Lymphocytic Leukemia Trial in Worldwide (Acalabrutinib (ACP-196), Rituximab, Idelalisib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Acalabrutinib (ACP-196)
  • +3 more
  • Chandler, Arizona
  • +156 more
Jun 2, 2022

Idelalisib in Patients With Refractory Follicular Lymphoma

Completed
  • Follicular Non-Hodgkin's Lymphoma Refractory
  • Idelalisib
  • Antwerpen, Belgium
  • +87 more
Nov 16, 2021

Lymphoid Malignancies Trial in Amsterdam (Idelalisib)

Terminated
Has Results
  • Lymphoid Malignancies
  • Idelalisib
  • Amsterdam, Netherlands
    (unnamed)
Feb 18, 2020

Influenza Vaccine in B-cell Malignancies Treated With Idelalisib

Terminated
  • B-cell Malignancies
  • Influenza Vaccine
  • Prague 10, Czechia
  • +1 more
Feb 18, 2020

Follicular Lymphoma, Mantle Cell Lymphoma Trial in Worldwide (BCL201, Idelalisib)

Completed
  • Follicular Lymphoma, Mantle Cell Lymphoma
  • New York, New York
  • +6 more
Feb 21, 2020